Wolfgang Miesbach: How Laboratory Strategies Must Evolve to Meet Expanding Haemophilia Therapies
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”An inspiring morning at EAHAD 2026 in Dublin: Annette Bowyer’s talk ‘Monitoring factor treatment in 2026 and beyond’ highlighted how rapidly our laboratory strategies must evolve to keep pace with the expanding spectrum of haemophilia therapies:
Monitoring needs to be tailored to the molecule and treatment class – from SHL/EHL/UHL concentrates to FVIII mimetics, gene therapy and emerging non‑factor therapies.
One‑stage and chromogenic assays each have strengths and limitations; for some products, results can be systematically over‑ or underestimated, demanding product‑specific approaches and clear lab–clinic communication.
Global assays of haemostasis and specific monitoring of FVIII mimetics and anti‑TFPI therapies are becoming increasingly important, but still require harmonisation and standardisation.
With more subcutaneous and non‑replacement options, the frequency and goals of monitoring are changing – from traditional peak/trough levels to efficacy, safety, inhibitor risk and transgene expression over the long term.
For haemophilia centres, this means closer collaboration between clinicians and specialised laboratories, investment in assay validation, and updated protocols to ensure safe, effective and personalised care in the era of innovative therapies.”
Stay updated with Hemostasis Today.
-
Oct 21, 2026, 03:36Steve Watson: Ligand Epitope Ratios Influence Antagonist Inhibition
-
Oct 21, 2026, 03:18Stephen D. Coombs: Superficial Venous Thrombosis in Athletes and Importance of Early Recognition and Referral
-
Oct 21, 2026, 02:52Aymar Akilimali: Bleeding During Anticoagulation as a Potential Signal of Occult Cancer
-
Oct 21, 2026, 00:58Anees Ur Rahman: Completing a Two-Week Clinical Rotation at Haemophilia Treatment Centre Rawalpindi
-
Oct 21, 2026, 00:56Caitlyn Mooney: Pulmonary Embolism in Athletes, Recognition and Return to Sport
-
Oct 21, 2026, 00:54Hani Karrar: Pleased to Share Our Review on Emicizumab in Hemophilia A Management
-
Oct 21, 2026, 00:53Akshay Sharma: HSCT Leads to Sustained Improvements in Sickle Cell Cardiomyopathy for Up to 3 Years
-
Oct 21, 2026, 00:51Prateek Meena: The F. A. T. R. N. Mnemonic for Recognizing TTP
-
Oct 20, 2026, 23:51Registration Is Open for WFH CCS 2027 – World Federation of Hemophilia